Simulations Plus

InnoGI Technologies and Simulations Plus Combine Forces to Offer Next-Level Modeling Solutions for the Prediction of Oral Drug Performance

Retrieved on: 
Mittwoch, April 17, 2024
Simulations Plus, Pharmacopoeia, USP, TIM, Solubility, Doctor of Philosophy, United States Pharmacopeia, PBPK, ADMET, MBA, Excipient, Medical device

DELFT, Netherlands, April 17, 2024 /PRNewswire/ -- InnoGI Technologies (formerly The TIM Company) is pleased to announce an exciting, market-driven collaboration with Simulations Plus to combine its TIM Technology, part of the InnoGI SurroGUT™ platform, with the GastroPlus® and ADMET Predictor® modelling software offered by Simulations Plus.

Key Points: 
  • DELFT, Netherlands, April 17, 2024 /PRNewswire/ -- InnoGI Technologies (formerly The TIM Company) is pleased to announce an exciting, market-driven collaboration with Simulations Plus to combine its TIM Technology, part of the InnoGI SurroGUT™ platform, with the GastroPlus® and ADMET Predictor® modelling software offered by Simulations Plus.
  • Understanding drug behavior following oral administration is important because solubility and absorption profiles affect dosing and efficacy.
  • However, dynamic interactions between sparingly-soluble active pharmaceutical ingredients, excipients and the gastrointestinal (GI) environment are oversimplified in all static in vitro dissolution models and are very difficult to model using purely computational (in silico) approaches.
  • This will improve the predictive accuracy of physiologically-based pharmacokinetic (PBPK) models, physiologically-based biopharmaceutics models (PBBMs), and facilitate the development of mechanistic IVIVCs."

U.S. FDA Renews DILIsym® Software Licenses for 7th Year

Retrieved on: 
Donnerstag, April 4, 2024
Data Management, Biotechnology, Technology, FDA, Health, Pharmaceutical, Health Technology, Research, Software, Artificial Intelligence, Science, Simulations Plus, Pharmacology, QST, Initiative, Partnership, Risk, QSP, SLP, Safety, Toxicology, Liver, Hepatotoxicity, Pharmaceutical industry

Dr. Paul B. Watkins, chair of the Scientific Advisory Board of the DILI-sim Initiative, said, “It is now known what properties to avoid to minimize liver toxicity in a new drug candidate -- but these same properties are often necessary to have therapeutic efficacy. By predicting safe dosing regimens of such drugs, DILIsym is now enabling successful development of important therapies that might otherwise be abandoned.”

Key Points: 
  • DILIsym is the industry gold standard for quantitative systems toxicology (QST) software designed for the prediction and investigation of drug-induced liver injury (DILI).
  • The one-year renewal provides the FDA with continued access to the DILIsym platform for authorized employees across all FDA divisions.
  • It also allows the FDA to evaluate the potential DILI risk across multiple populations, which supports informed decision-making regarding drug approvals.
  • Companies interested in a free trial version of the DILIsym software can request it here .

Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date

Retrieved on: 
Mittwoch, März 20, 2024
Software, Research, General Health, Professional Services, Pharmaceutical, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Consulting, Health, Simulations Plus, Webcast, SLP

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024.
  • Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results.
  • Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here .
  • The webcast can be accessed on the investor relations page of the Simulations Plus website at www.simulations-plus.com/investorscorporate-profile/corporate-profile/ where it will also be available for replay approximately one hour following the call.

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Retrieved on: 
Mittwoch, März 13, 2024
Technology, Health Technology, Software, Biotechnology, Internet, Health, Pharmaceutical, Data Management, Artificial Intelligence, Simulations Plus, SLP, Medtech

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn O’Connor, chief executive officer, will be hosting a fireside chat at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 4:30 p.m. Eastern Time.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn O’Connor, chief executive officer, will be hosting a fireside chat at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 4:30 p.m. Eastern Time.
  • In addition, Mr. O’Connor will be meeting one-on-one with investors throughout the day.
  • The live webcast of the Company’s presentation can be accessed via this link and also on the Investors page of the Simulations Plus website where it will be available for replay for approximately 90 days following the event.

Splash Beverage Group Appoints Dr. John Paglia, a Professor of Finance at Pepperdine Graziadio Business School, to Its Board of Directors

Retrieved on: 
Freitag, März 1, 2024
Pepperdine University, Bloomberg Businessweek, CPA, Certified Public Accountant, University, Gannon University, Entrepreneurship, Small business, Chartered Financial Analyst, Growth, Drug discovery, MBA, CFA, Library, Audit committee, Faculty, The Wall Street Journal, Simulations Plus, Pepperdine Graziadio Business School, Congress, CNBC, SBIC, Research, Management

Dr. Paglia, age 56, is a tenured Professor of Finance at the Pepperdine Graziadio Business School where he teaches graduate level classes on the topics of corporate finance, business valuation, and mergers and acquisitions.

Key Points: 
  • Dr. Paglia, age 56, is a tenured Professor of Finance at the Pepperdine Graziadio Business School where he teaches graduate level classes on the topics of corporate finance, business valuation, and mergers and acquisitions.
  • in Finance from Gannon University, and is a Certified Public Accountant, Chartered Financial Analyst, and is NACD Directorship Certified™.
  • "We are honored to welcome John to our board of directors," said Robert Nistico, CEO and Chairman of Splash Beverage Group.
  • As a board member, I look forward to contributing to Splash’s vision and growth while working to increase shareholder value."

Simulations Plus and the University of Bath Awarded New FDA Grant

Retrieved on: 
Dienstag, März 5, 2024
Research, FDA, Public Relations, Investor Relations, Clinical Trials, Communications, Biotechnology, Pharmaceutical, Health, Science, Other Science, SLP, Human services, Name, University, Professor, Food, Drug development, Colorado School of Mines, Skin, Government, Simulations Plus, Patient, University of Reading

“Collaborating with the University of Bath and other partners on this groundbreaking FDA grant is a remarkable opportunity.

Key Points: 
  • “Collaborating with the University of Bath and other partners on this groundbreaking FDA grant is a remarkable opportunity.
  • By doing so, we aim to significantly expedite the regulatory decision-making process, ultimately benefiting patients and the pharmaceutical industry.”
    FDA scientific and program staff will actively collaborate with the University of Bath, Colorado School of Mines, University of Reading, and Simulations Plus.
  • Le Merdy , with assistance from Dr. Jessica Spires and Dr. Jasmina Novakovic at Simulations Plus, will coordinate modeling and simulation activities of the contract.
  • “By combining our expertise with Simulations Plus’ cutting-edge research, we are charting a course towards more efficient drug development and safer healthcare solutions.

Simulations Plus Extends Collaboration with Major Toxicology Research Agency

Retrieved on: 
Donnerstag, Februar 15, 2024
Health, Technology, Software, Research, Science, Pharmaceutical, Biotechnology, SLP, Environ, Division, Metabolism, Toxicology, Toxicity, North American Menopause Society, Absorption, Biopharmaceutical, Animal, NIEHS, Skin, Risk, Vivo, ADMET, Safety, DTT, Computation, Cheminformatics, Environmental health, Pharmacokinetics, Simulations Plus, Child, Machine learning, Human, Environment, Pharmaceutical industry

“At NIEHS, we seek to expand scientific knowledge and approach methods linking the environment and human health.

Key Points: 
  • “At NIEHS, we seek to expand scientific knowledge and approach methods linking the environment and human health.
  • “Importantly, these tools are being investigated for their potential to address a critical gap in toxicology research for understanding and modeling human bioactivation of environmental chemicals through xenobiotic metabolism,” Ferguson added.
  • Principal Scientist in the Cheminformatics Solutions team at Simulations Plus.
  • It is the leading physiologically based pharmacokinetic/physiologically based biopharmaceutics modeling (PBPK/PBBM) platform, built and refined over 25 years on the most up-to-date scientific research.

Simulations Plus Launches Corporate Development Initiative

Retrieved on: 
Dienstag, Februar 13, 2024
Health, Technology, Software, Artificial Intelligence, Pharmaceutical, Biotechnology, SLP, Computational biology, Emerging, Drug design, TAM, Simulations Plus, Chemistry, Research, Investment, Management

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today provided additional information on advancing its corporate allocation strategy, specifically increased focus on strategic investments and partnerships.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today provided additional information on advancing its corporate allocation strategy, specifically increased focus on strategic investments and partnerships.
  • Simulations Plus will actively pursue investments and partnerships in early-stage technology companies aimed at accelerating software and services innovations, increasing technology leadership in computational biology and chemistry, expanding total market opportunity, and identifying potential M&A candidates.
  • Enhance Innovation and Adoption of Emerging Technologies: Explore software and services innovation and seek deeper visibility into evolving technologies, including artificial intelligence-driven drug design (AIDD) and development.
  • “Our team is very excited to launch this corporate development initiative and formalize our corporate development programs with the flexibility to make strategic investments and form joint partnerships in early-stage companies,” said Will Frederick, Chief Financial Officer and Chief Operating Officer.

Simulations Plus to Participate in Upcoming Healthcare Conferences

Retrieved on: 
Dienstag, Februar 6, 2024
Health, Technology, Health Technology, Software, Pharmaceutical, Biotechnology, Digital health, Simulations Plus, SLP, Conference, Cryptocurrency

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February.
  • The Company will be presenting at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13-14, 2024.
  • For more information about the Oppenheimer Annual Healthcare Conference, or to register to attend, please visit the conference website .
  • The Company’s slide presentation will be available on the Investors page of the Simulations Plus website.

Simulations Plus Releases GastroPlus® Version 9.9

Retrieved on: 
Dienstag, Januar 30, 2024
Biotechnology, Pharmaceutical, Public Relations, Investor Relations, Health, FDA, Communications, Chemicals, Plastics, Manufacturing, Simulations Plus, Research, Patient, Safety, ADMET, SLP, ADR, Human

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the release of GastroPlus® 9.9, the latest version of its flagship physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the release of GastroPlus® 9.9, the latest version of its flagship physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software.
  • Upgraded with ADMET Predictor® version 11 models, enhancing our First in Human Simulator
    “Our software updates reflect the needs our customers communicate to us, and GastroPlus 9.9 is no exception,” said Neil Miller , Vice President of Simulation Sciences at Simulations Plus.
  • “We incorporated feedback from more than 100 companies into these latest enhancements, ensuring they truly provide the improved functionality our customers require.
  • “This is one reason our clients know they can rely on data generated with GastroPlus to inform their program design and support regulatory submissions.